Lipocine

$1.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-2.52%) Today
+$0.03 (+1.94%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Lipocine and other stocks, options, and ETFs commission-free!

About LPCN

Lipocine Inc. Common Stock, also called Lipocine, is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT. The listed name for LPCN is Lipocine Inc. Common Stock.

CEO
Mahesh V. Patel
Employees
12
Headquarters
Salt Lake City, Utah
Founded
2011
Market Cap
138.23M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.69M
High Today
$1.65
Low Today
$1.53
Open Price
$1.62
Volume
1.77M
52 Week High
$2.42
52 Week Low
$0.301

LPCN Earnings

-$0.16
-$0.11
-$0.05
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 11, Pre-Market

You May Also Like

NULC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure